Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A

Expert Review of Hematology

Volumn 8, Issue 4, 2015, Pages 427-432

  Gomperts, Edward ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

acquired hemophilia A; factor VIII; hemophilia A; inhibitor; OBIZUR; recombinant porcine FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT B DOMAIN DELETED PORCINE FACTOR VIII; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8A; RECOMBINANT PROTEIN;

ACQUIRED HEMOPHILIA A; ADULT; AMINO ACID SEQUENCE; AREA UNDER THE CURVE; BLEEDING; DRUG EFFICACY; DRUG PURITY; DRUG SAFETY; HEMOPHILIA A; HEMOSTASIS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANIMAL; PIG; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR VIIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SWINE; TREATMENT OUTCOME;

EID: 84936938891     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1040758     Document Type: Review

References (29)

1. Montgomery RR, Gill JC, Scott JP. Hemophilia and von Willebrand disease. In: Nathan and Oski's hematology of infancy and childhood Nathan DG, Orkin SH, Ginsburg D, Look AT, editors. Hemophilia and von Willebrand Disease in Hematology of Infancy and Childhood O.S. 6th edition. WB Saunders; Philadelphia, PA, USA: 2003. p. 1547-76
2. Dimichele D. Chapter 11. Inhibitors to factor VIII-epidemiology and treatment. In: Textbook of Hemophilia. Lee CA, Berntorp EE, Hoots WK, Aledort LM, editors. Textbook of Hemophilia. Blackwell Publishing Ltd; Oxford, UK: 2005. p. 64-70
3. Kessler CM, Asatiani E. Acquired inhibitors to factor VIII. In: Berntorp EE, Keith Hoots W, Lee CA, editor. Textbook of Hemophilia. Wiley-Blackwell; Oxford, UK: 2005. p. 86-90
4. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008;112(2):250-5
5. Baudo F, Collins P, Huth-K?thne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012;120(1):39-46
6. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5(5):893-900
7. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007;13(5):451-61
8. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8(2): 83-90
9. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109(2):546-51
10. de Paula EV, Kavakli K, Mahlangu J, et al. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012;10(1):81-9
11. Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006;95(4):600-5
12. Giangrande PL. Porcine factor VIII. Haemophilia 2012;18(3):305-9
13. Hay C, Lozier JN. Porcine factor VIII therapy in patients with factor VIII inhibitors. Adv Exp Med Biol 1995;386: 143-51
14. Negrier C. The use of porcine factor VIII in France. Semin Hematol 1994; 31(2 Suppl 4):29-32
15. Griggs TR, Webster WP, Cooper HA, et al. Von Willebrand factor: gene dosage relationships and transfusion response in bleeder swine-a new bioassay. Proc Natl Acad Sci USA 1974;71:2087-90
16. Bahnak BR, Lavergne JM, Ferreira V, et al. Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesion. Biochem Biophys Res Commun 1992;182:561-8
17. Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989;149(6):1381-5
18. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81(6):1513-20
19. Hay CR, Lozier JN, Lee CA, et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Semin Hematol 1994;31(2 Suppl 4):20-5
20. Doering CB, Healey JF, Parker ET, et al. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002;277(41):38345-9
21. Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996;88(11): 4209-14
22. Bergman GE, Lillicrap D, Robinson P. Cross-over comparative study of tolerability, pharmacokinetics and efficacy of two forms of porcine Factor VIII in the canine model of hemophilia A. J Thromb Haemost 2005; 3(Suppl 1):abstract no. PO835
23. Kempton CL, Abshire TC, Deveras RA, et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012;18(5):798-804
24. Mahlangu J, Andreeva TA, Macfarlane DE, et al. A Phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia a patients with alloantibody inhibitors directed against human FVIII. In: American Society of Hematology. Blood Atlanta, GA, USA; 2007
25. Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015;21(2): 162-70
26. Kyhos B. FDA approves Baxter's OBIZUR [antihemophilic factor (recombinant), procine sequence], for acquired hemophilia A. Baxter International Inc, Baxter website. 2014. p. 1-5
27. Gomes H, Martinez F, Robelo B, et al. Delayed diagnosis of pulmonary embolism in a patient with a prior history of acquired haemophilia. Haemophilia 2015; 21(Suppl 2):14-94; Abstract PP044
28. Hay C. Porcine factor VIII: current status and future developments. Haemophilia 2002;8(Suppl 1):24-7
29. Hay C, Lozier JN, Lee CA, et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996;75:25-9